Sulfamethoxazole And Trimethoprim (Sulfamethoxazole And Trimethoprim)

Trade Name : Sulfamethoxazole and Trimethoprim

Mylan Institutional LLC

INJECTION

Strength 8016 mg/mLmg/mL

SULFAMETHOXAZOLE; TRIMETHOPRIM Sulfonamide Antimicrobial [EPC],Sulfonamides [CS],Cytochrome P450 2C9 Inhibitors [MoA],Dihydrofolate Reductase Inhibitor Antibacterial [EPC],Dihydrofolate Reductase Inhibitors [MoA],Cytochrome P450 2C8 Inhibitors [MoA],Organic Cation Transporter 2 Inhibitors [MoA]

Delivery Process

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Sulfamethoxazole And Trimethoprim (Sulfamethoxazole And Trimethoprim) which is also known as Sulfamethoxazole and Trimethoprim and Manufactured by Mylan Institutional LLC. It is available in strength of 80; 16 mg/mL; mg/mL per ml. Read more

Sulfamethoxazole And Trimethoprim (Sulfamethoxazole And Trimethoprim) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • Indications and Usage () 7/2020
  • Sulfamethoxazole and trimethoprim injection is a combination of sulfamethoxazole, a sulfonamide antimicrobial, and trimethoprim, a dihydrofolate reductase inhibitor antibacterial, indicated in adults and pediatric patients two months of age and older for treatment of infections caused by designated, susceptible bacteria.
  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim injection and other antibacterial drugs, sulfamethoxazole and trimethoprim injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ()
  • Pneumocystis jirovecii
  • No data
  • Sulfamethoxazole and trimethoprim injection, USP is available as an injection containing 80 mg/mL of sulfamethoxazole and 16 mg/mL of trimethoprim in 5 mL single-dose and 30 mL multiple-dose vials.
  • Injection: 80 mg/mL sulfamethoxazole and 16 mg/mL trimethoprim in 5 mL single-dose and 30 mL multiple-dose vials. ()
  • Sulfamethoxazole and trimethoprim is contraindicated in the following:
  • No data
  • Clostridioides difficile
  • Pneumocystis jirovecii
  • The following serious adverse reactions are described elsewhere in the labeling:
  • The most common adverse effects are gastrointestinal disturbances (nausea, vomiting, and anorexia) and allergic skin reactions (such as rash and urticaria). ()
  • To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or n
  • Potential for Sulfamethoxazole and Trimethoprim to Affect Other Drugs
  • Trimethoprim is an inhibitor of CYP2C8 as well as OCT2 transporter. Sulfamethoxazole is an inhibitor of CYP2C9. Avoid coadministration of sulfamethoxazole and trimethoprim with drugs that are substrates of CYP2C8 and 2C9 or OCT2
  • Table 4: Drug Interactions with Sulfamethoxazole and Trimethoprim Injection
  • Sulfamethoxazole and trimethoprim, specifically the trimethoprim component, can interfere with a serum methotrexate assay as determined by the competitive binding protein technique (CBPA) when a bacterial dihydrofolate reductase is used as the binding protein. No interference occurs, however, if methotrexate is measured by a radioimmunoassay (RIA).
  • The presence of sulfamethoxazole and trimethoprim may also interfere with the Jaffu00e9 alkaline picrate reaction assay for creatinine, resulting in overestimations of about 10% in the range of normal values.
  • No data
  • Acute
  • Since there has been no extensive experience in humans with single doses of sulfamethoxazole and trimethoprim in excess of 25 mL (400 mg trimethoprim and 2000 mg sulfamethoxazole), the maximum tolerated dose in humans is unknown.
  • Signs and symptoms of overdosage reported with sulfonamides include anorexia, colic, nausea, vomiting, dizziness, headache, drowsiness and unconsciousness. Pyrexia, hematuria and crystalluria may be noted. Blood dyscrasias and jaundice are potential late manifestations of overdosage.
  • Signs of acute overdosage with trimethoprim include nausea, vomiting, dizziness, headache, mental depression, confusion and bone marrow depression.
  • General principles of treatment include the administration of intravenous fluids if urine output is low and renal function is normal. Acidification of the urine will increase renal elimination of trimethoprim. The patient should be monitored with blood counts and appropriate blood chemistries, including electrolytes. If a significant blood dyscrasia or jaundice occurs, specific therapy should be instituted for these complications. Peritoneal dialysis is not effective and hemodialysis is only moderately effective in eliminating trimethoprim and sulfamethoxazole.
  • Chronic
  • Use of sulfamethoxazole and trimethoprim at high doses and/or for extended periods of time may cause bone marrow depression manifested as thrombocytopenia, leukopenia and/or megaloblastic anemia. If signs of bone marrow depression occur, the patient should be given leucovorin 5 to 15 mg daily until normal hematopoiesis is restored.
  • Sulfamethoxazole and trimethoprim injection USP, a sterile, clear, colorless or slightly yellow solution for intravenous infusion only, is a combination of sulfamethoxazole, a sulfonamide antimicrobial, and trimethoprim, a dihydrofolate reductase inhibitor antibacterial. Each mL contains 16 mg trimethoprim, USP and 80 mg sulfamethoxazole, USP compounded with propylene glycol 400 mg (38.6% v/v and 40.0% w/v); dehydrated alcohol 100 mg (12.3% v/v and 10.0% w/v); diethanolamine 3 mg (0.3% v/v and 0.3% w/v); benzyl alcohol 10 mg (1.0% v/v and 1.0% w/v) as a preservative; sodium metabisulfite 1 mg (0.1% w/v) as an antioxidant; water for injection q.s.; air replaced with nitrogen; pH adjusted with sodium hydroxide and/or hydrochloric acid if necessary. pH 9.5 to 10.5.
  • Trimethoprim, USP is 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine. It is a white to light yellow, odorless, bitter compound with a molecular weight of 290.3 and the following structural formula:
  • CHNO M.W. 290.3
  • Sulfamethoxazole, USP is -(5-methyl-3-isoxazolyl) sulfanilamide. It is an almost white, odorless, tasteless compound with a molecular weight of 253.28 and the following structural formula:
  • CHNOS M.W. 253.28
  • No data
  • Carcinogenesis
  • Sulfamethoxazole was not carcinogenic when assessed in a 26-week tumorigenic mouse (Tg-rasH2) study at doses up to 400 mg/kg/day sulfamethoxazole; equivalent to 2-fold the human systemic exposure (at a daily dose of 800 mg sulfamethoxazole .
  • Mutagenesis
  • In vitro
  • in vitro
  • in vitro
  • in vivo
  • In vivo
  • Sulfamethoxazole alone was positive in an reverse mutation bacterial assay and in micronucleus assays using cultured human lymphocytes.
  • Trimethoprim alone was negative in reverse mutation bacterial assays and in chromosomal aberration assays with Chinese Hamster ovary or lung cells with or without S9 activation. In Comet, micronucleus and chromosomal damage assays using cultured human lymphocytes, trimethoprim was positive. In mice following oral administration of trimethoprim, no DNA damage in Comet assays of liver, kidney, lung, spleen, or bone marrow was recorded.
  • Impairment of Fertility
  • No adverse effects on fertility or general reproductive performance were observed in rats given oral dosages as high as 350 mg/kg/day sulfamethoxazole plus 70 mg/kg/day trimethoprim, doses roughly two times the recommended human daily dose on a body surface area basis.
  • No data
  • Sulfamethoxazole and trimethoprim injection, USP is supplied as follows:
  • 5 mL Single-Dose Vialscontaining 80 mg trimethoprim (16 mg/mL) and 400 mg sulfamethoxazole (80 mg/mL) for infusion with 5% dextrose in water.
  • 30 mL Multiple-Dose Vialseach 5 mL containing 80 mg trimethoprim (16 mg/mL) and 400 mg sulfamethoxazole (80 mg/mL) for infusion with 5% dextrose in water.
  • After initial entry into vial, the remaining contents must be used within 48 hours.
  • Store at 20u00b0 to 25u00b0C [68u00b0 to 77u00b0F]. [See USP Controlled Room Temperature]. n- DO NOT REFRIGERATE.
  • Arrayn- Embryou2013fetal Toxicity
  • Advise female patients of reproductive potential that sulfamethoxazole and trimethoprim can cause fetal harm and to inform their healthcare provider of a known or suspected pregnancy .
  • Arrayn- Lactation
  • Advise nursing women to avoid breastfeeding during treatment with sulfamethoxazole and trimethoprim.
  • Arrayn- Antibacterial Resistance
  • Counsel patients that antibacterial drugs including sulfamethoxazole and trimethoprim should only be used to treat bacterial infections. It does not treat viral infections (e.g., the common cold).
  • Instruct patients to maintain an adequate fluid intake in order to prevent crystalluria and stone formation.
  • Arrayn- Diarrhea
  • Advise patients that diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
  • Manufactured for:
  • Mylan Institutional LLC
  • Morgantown, WV 26505 U.S.A.
  • Manufactured by:
  • Mylan Laboratories Limited
  • Bangalore, India
  • DECEMBER 2020
  • NDC 67457-778-05
  • Sulfamethoxazole and Trimethoprim Injection, USP
  • Sulfamethoxazole 400 mg/5mL (80 mg/mL)
  • Trimethoprim 80 mg/5 mL (16 mg/mL)
  • For Intravenous Infusion Only
  • Must be diluted with 5% dextrose injection prior to administration
  • Sterile
  • Mylan
  • Rx only
  • 10 x 5 mL Single-Dose Vials
  • NDC 67457-779-30
  • Sulfamethoxazole and Trimethoprim Injection, USP
  • Sulfamethoxazole 400 mg/5mL (80 mg/mL)
  • Trimethoprim 80 mg/5 mL (16 mg/mL)
  • For Intravenous Infusion Only
  • Must be diluted with 5% dextrose injection prior to administration
  • Sterile
  • Mylan
  • Rx only
  • 30 mL Multiple-Dose Vials

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71245 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.